{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:20:27Z","timestamp":1790824827245,"version":"4.1.0"},"reference-count":54,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>von Willebrand disease (VWD) is the most common autosomally inherited bleeding disorder. The disease represents a range of quantitative and qualitative pathologies of the adhesive glycoprotein von Willebrand factor (VWF). The pathogenic mechanisms responsible for the type 2 qualitative variants of VWF are now well characterized, with most mutations representing missense substitutions influencing VWF multimer structure and interactions with platelet GPIb\u03b1 and collagen and with factor VIII. The molecular pathology of type 3 VWD has been similarly well characterized, with an array of different mutation types producing either a null phenotype or the production of VWF that is not secreted. In contrast, the pathogenetic mechanisms responsible for type 1 VWD remain only partially resolved. In the hemostasis laboratory, the measurement of VWF:Ag and VWF:RCo are key components in the diagnostic algorithm for VWD, although the introduction of direct GPIb\u03b1-binding assays may become the functional assay of choice. Molecular genetic testing can provide additional benefit, but its utility is currently limited to type 2 and 3 VWD. The treatment of bleeding in VWD involves the use of desmopressin and plasma-derived VWF concentrates and a variety of adjunctive agents. Finally, a new recombinant VWF concentrate has just completed clinical trial evaluation and has demonstrated excellent hemostatic efficacy and safety.<\/jats:p>","DOI":"10.1182\/asheducation-2013.1.254","type":"journal-article","created":{"date-parts":[[2013,12,6]],"date-time":"2013-12-06T15:51:13Z","timestamp":1386345073000},"page":"254-260","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":39,"title":["von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy"],"prefix":"10.1182","volume":"2013","author":[{"given":"David","family":"Lillicrap","sequence":"first","affiliation":[{"name":"Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4706","key":"2019111705081983400_B1","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1126\/science.3874428","article-title":"Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localization","volume":"228","author":"Ginsburg","year":"1985","journal-title":"Science"},{"issue":"1","key":"2019111705081983400_B2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0092-8674(85)90060-1","article-title":"Molecular cloning of cDNA for human von Willebrand factor: authentication by a new method","volume":"41","author":"Lynch","year":"1985","journal-title":"Cell"},{"issue":"19","key":"2019111705081983400_B3","doi-asserted-by":"crossref","first-page":"6394","DOI":"10.1073\/pnas.82.19.6394","article-title":"Cloning and characterization of two cDNAs coding for human von Willebrand factor","volume":"82","author":"Sadler","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"2019111705081983400_B4","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1093\/nar\/13.13.4699","article-title":"Construction of cDNA coding for human von Willebrand factor using antibody probes for colony-screening and mapping of the chromosomal gene","volume":"13","author":"Verweij","year":"1985","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2019111705081983400_B5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1538-7836.2009.03661.x","article-title":"The prevalence of symptomatic von Willebrand disease in primary care practice","volume":"8","author":"Bowman","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2019111705081983400_B6","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood.V69.2.454.454","article-title":"Epidemiological investigation of the prevalence of von Willebrand's disease","volume":"69","author":"Rodeghiero","year":"1987","journal-title":"Blood"},{"issue":"7","key":"2019111705081983400_B7","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0025-6196(12)62088-6","article-title":"von Willebrand factor: clinical features of inherited and acquired disorders","volume":"66","author":"Bloom","year":"1991","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"2019111705081983400_B8","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1111\/j.1538-7836.2006.02146.x","article-title":"Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor","volume":"4","author":"Sadler","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2019111705081983400_B9","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1182\/blood-2012-01-405134","article-title":"Sequence and structure relationships within von Willebrand factor","volume":"120","author":"Zhou","year":"2012","journal-title":"Blood"},{"issue":"19","key":"2019111705081983400_B10","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1182\/blood-2011-06-360875","article-title":"Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage","volume":"119","author":"Jacobi","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2019111705081983400_B11","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/j.1538-7836.2012.04675.x","article-title":"Use of a mouse model to elucidate the phenotypic effects of the von Willebrand factor cleavage mutants, Y1605A\/M1606A and R1597W","volume":"10","author":"Pruss","year":"2012","journal-title":"J Thromb Haemost"},{"key":"2019111705081983400_B12","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1182\/blood-2008-04-152280","article-title":"Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: A cohort study of 67 patients","volume":"113","author":"Federici","year":"2009","journal-title":"Blood"},{"issue":"23","key":"2019111705081983400_B13","doi-asserted-by":"crossref","first-page":"4870","DOI":"10.1182\/blood-2009-11-254193","article-title":"Mutation and ADAMTS13-dependent modulation of disease severity in a mouse model for von Willebrand disease type 2B","volume":"115","author":"Rayes","year":"2010","journal-title":"Blood"},{"issue":"23","key":"2019111705081983400_B14","doi-asserted-by":"crossref","first-page":"4862","DOI":"10.1182\/blood-2009-11-253120","article-title":"Mutation-specific hemostatic variability in mice expressing common type 2B von Willebrand disease substitutions","volume":"115","author":"Golder","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2019111705081983400_B15","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1055\/s-2007-1000368","article-title":"Platelet-type von Willebrand disease and type 2B von Willebrand disease: a story of nonidentical twins when two different genetic abnormalities evolve into similar phenotypes","volume":"33","author":"Othman","year":"2007","journal-title":"Semin Thromb Hemost"},{"key":"2019111705081983400_B16","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1055\/s-0037-1616142","article-title":"Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen","volume":"86","author":"Ribba","year":"2001","journal-title":"Thromb Haemost"},{"key":"2019111705081983400_B17","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2008-10-184317","article-title":"Characterisation of W1745C and S1783A, two novel collagen binding defects in the A3 domain of von Willebrand factor","volume":"114","author":"Riddell","year":"2009","journal-title":"Blood"},{"issue":"7","key":"2019111705081983400_B18","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/j.1538-7836.2012.04746.x","article-title":"Critical von Willebrand factor A1 domain residues influence type VI collagen binding","volume":"10","author":"Flood","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2019111705081983400_B19","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/beha.2001.0138","article-title":"Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology","volume":"14","author":"Mazurier","year":"2001","journal-title":"Best Pract Res Clin Haematol"},{"key":"2019111705081983400_B20","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1053\/beha.2001.0139","article-title":"Congenital von Willebrand disease type 3: clinical manifestations, pathophysiology and molecular biology","volume":"14","author":"Eikenboom","year":"2001","journal-title":"Best Pract Res Clin Haematol"},{"key":"2019111705081983400_B21","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/jth.12130","article-title":"The genetics of Canadian type 3 von Willebrand Disease (VWD): further evidence for co-dominant inheritance of mutant alleles","volume":"11","author":"Bowman","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"8","key":"2019111705081983400_B22","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1073\/pnas.85.8.2753","article-title":"Homozygous and heterozygous deletions of the von Willebrand factor gene in patients and carriers of severe von Willebrand disease","volume":"85","author":"Ngo","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2019111705081983400_B23","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1172\/JCI112974","article-title":"Gene deletions correlate with the development of alloantibodies in von Willebrand disease","volume":"79","author":"Shelton-Inloes","year":"1987","journal-title":"J Clin Invest"},{"key":"2019111705081983400_B24","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood-2012-10-462085","article-title":"Alloantibodies in von Willebrand disease","volume":"122","author":"James","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2019111705081983400_B25","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1182\/blood-2006-05-021105","article-title":"The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study","volume":"109","author":"James","year":"2007","journal-title":"Blood"},{"issue":"1","key":"2019111705081983400_B26","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood-2006-05-020784","article-title":"Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD)","volume":"109","author":"Goodeve","year":"2007","journal-title":"Blood"},{"issue":"5","key":"2019111705081983400_B27","first-page":"630","article-title":"An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease","volume":"96","author":"Cumming","year":"2006","journal-title":"Thromb Haemost"},{"key":"2019111705081983400_B28","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1182\/blood-2011-10-384610","article-title":"Von Willebrand factor mutations and new sequence variations identified in healthy controls are more frequent in the African-American population","volume":"119","author":"Bellissimo","year":"2012","journal-title":"Blood"},{"issue":"18","key":"2019111705081983400_B29","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1182\/blood-2009-12-261131","article-title":"Functional characterization of a 13 bp deletion (c.-1522_-1510del13) in the promoter of the von Willebrand factor gene in type 1 von Willebrand disease","volume":"116","author":"Othman","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2019111705081983400_B30","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1538-7836.2009.03486.x","article-title":"Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM-1VWD study","volume":"7","author":"Eikenboom","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"10","key":"2019111705081983400_B31","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1182\/blood-2007-09-110940","article-title":"Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD)","volume":"111","author":"Haberichter","year":"2008","journal-title":"Blood"},{"issue":"10","key":"2019111705081983400_B32","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1182\/blood-2006-04-015065","article-title":"Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival","volume":"108","author":"Haberichter","year":"2006","journal-title":"Blood"},{"issue":"14","key":"2019111705081983400_B33","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1182\/blood-2012-06-435727","article-title":"Cellular and molecular basis of von Willebrand disease: studies on blood outgrowth endothelial cells","volume":"121","author":"Starke","year":"2013","journal-title":"Blood"},{"issue":"14","key":"2019111705081983400_B34","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1182\/blood-2012-06-434373","article-title":"Analysis of the storage and secretion of von Willebrand factor in blood outgrowth endothelial cells derived from patients with von Willebrand disease","volume":"121","author":"Wang","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2019111705081983400_B35","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood.V69.6.1691.1691","article-title":"The effect of ABO blood group on the diagnosis of von Willebrand disease","volume":"69","author":"Gill","year":"1987","journal-title":"Blood"},{"issue":"12","key":"2019111705081983400_B36","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1161\/CIRCULATIONAHA.109.869156","article-title":"Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium","volume":"121","author":"Smith","year":"2010","journal-title":"Circulation"},{"key":"2019111705081983400_B37","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1182\/blood-2012-10-457507","article-title":"The C-type lectin receptor CLEC4M binds, internalizes and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels","volume":"121","author":"Rydz","year":"2013","journal-title":"Blood"},{"key":"2019111705081983400_B38","article-title":"The evolution and value of bleeding assessment tools","author":"Rydz","journal-title":"J Thromb Haemost"},{"issue":"12","key":"2019111705081983400_B39","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1111\/j.1538-7836.2008.03182.x","article-title":"Generation and validation of the Condensed MCMDM-1VWD bleeding questionnaire for von Willebrand disease","volume":"6","author":"Bowman","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2019111705081983400_B40","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1538-7836.2006.01847.x","article-title":"A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD)","volume":"4","author":"Tosetto","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2019111705081983400_B41","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1182\/blood-2010-08-299016","article-title":"Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD","volume":"117","author":"Flood","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2019111705081983400_B42","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/hae.12064","article-title":"A comparative evaluation of a new automated assay for von Willebrand factor activity","volume":"19","author":"Lawrie","year":"2013","journal-title":"Haemophilia"},{"issue":"2","key":"2019111705081983400_B43","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1182\/blood-2009-10-249102","article-title":"Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor","volume":"116","author":"Flood","year":"2010","journal-title":"Blood"},{"issue":"18","key":"2019111705081983400_B44","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1182\/blood-2012-12-471672","article-title":"No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation","volume":"121","author":"Flood","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2019111705081983400_B45","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1111\/j.1538-7836.2012.04747.x","article-title":"Comparison of type I, type III and type VI collagen binding assays in diagnosis of von Willebrand disease","volume":"10","author":"Flood","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2019111705081983400_B46","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1182\/blood.V97.7.1915","article-title":"How I treat patients with von Willebrand disease","volume":"97","author":"Mannucci","year":"2001","journal-title":"Blood"},{"issue":"6","key":"2019111705081983400_B47","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1182\/blood-2009-01-153296","article-title":"How I treat von Willebrand disease","volume":"114","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"key":"2019111705081983400_B48","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2516.2007.01610.x","article-title":"The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977-2007)","volume":"14","author":"Federici","year":"2008","journal-title":"Haemophilia"},{"issue":"5","key":"2019111705081983400_B49","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3324\/haematol.2012.077263","article-title":"Principles of care for the diagnosis and treatment of von Willebrand disease","volume":"98","author":"Castaman","year":"2013","journal-title":"Haematologica"},{"issue":"12","key":"2019111705081983400_B50","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1111\/j.1471-0528.2004.00305.x","article-title":"The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders","volume":"111","author":"Kingman","year":"2004","journal-title":"BJOG"},{"issue":"6","key":"2019111705081983400_B51","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1055\/s-2006-949668","article-title":"Comparative analysis and classification of von Willebrand factor\/factor VIII concentrates: impact on treatment of patients with von Willebrand disease","volume":"32","author":"Budde","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"2019111705081983400_B52","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2516.2008.01851.x","article-title":"Prophylaxis in von Willebrand disease","volume":"14","author":"Berntorp","year":"2008","journal-title":"Haemophilia"},{"key":"2019111705081983400_B53","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1182\/blood-2013-01-479527","article-title":"Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial","volume":"122","author":"Mannucci","year":"2013","journal-title":"Blood"},{"issue":"12","key":"2019111705081983400_B54","doi-asserted-by":"crossref","first-page":"4728","DOI":"10.1182\/blood-2005-09-3605","article-title":"Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor","volume":"107","author":"De Meyer","year":"2006","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2013\/1\/254\/1249503\/bep00113000254.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2013\/1\/254\/1249503\/bep00113000254.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T10:08:43Z","timestamp":1573985323000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2013\/1\/254\/20743\/von-Willebrand-disease-advances-in-pathogenetic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,6]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2013.1.254","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,6]]}}}